In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer. The findings will be presented in a news briefing and the plenary session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) next week.